BridgeBio to present Phase 3 CALIBRATE trial results at European congress
BridgeBio Pharma Inc. (NASDAQ: BBIO) will present primary results from its Phase 3 CALIBRATE trial of encaleret for autosomal dominant ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)